memantine has been researched along with Chronic Disease in 25 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo." | 9.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "We conducted a randomized, double-blind, placebo-controlled, parallel-group study of both memantine and constraint-induced aphasia therapy (CIAT) on chronic poststroke aphasia followed by an open-label extension phase." | 9.14 | Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. ( Barbancho, MA; Berthier, ML; Dávila, G; Green, C; Higueras, C; Lara, JP; Pulvermüller, F, 2009) |
| "In the present study we investigated the effect of the N-methyl-D-aspartic acid (NMDA) receptor antagonist memantine (30 mg/d) on the intensity of chronic phantom limb pain (PLP) and cortical reorganization." | 9.11 | A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. ( Birbaumer, N; Braun, C; Flor, H; Kiefer, RT; Preissl, H; Töpfner, S; Unertl, K; Wiech, K, 2004) |
| "In a randomized, double-blinded and cross-over study, the analgesic effect of memantine (a drug which reduces the excitability of sensitized neurons in the dorsal horn) was examined in 19 patients with chronic pain after nerve injury." | 9.09 | Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. ( Gottrup, H; Jensen, TS; Kristensen, AG; Nikolajsen, L, 2000) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "Memantine was shown to reduce pain intensity in CTTH patients, albeit to a limited extent." | 6.74 | Memantine for prophylaxis of chronic tension-type headache--a double-blind, randomized, crossover clinical trial. ( Bendtsen, L; Lindelof, K, 2009) |
| " The administration of a higher dosage is probably not tolerable." | 6.71 | Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain--results of a randomized double-blinded, placebo-controlled trial. ( Dertwinkel, R; Hosbach, I; Maier, C; Mansourian, N; Schwenkreis, P; Senne, I; Skipka, G; Tegenthoff, M; Zenz, M, 2003) |
| "Memantine was well tolerated in all studies." | 6.53 | Memantine for the Treatment of Phantom Limb Pain: A Systematic Review. ( Britt, RB; Brown, JN; Loy, BM, 2016) |
| "Memantine treatment reversed anhedonia and the increase of adrenal gland weight, normalized corticosterone levels and increased BDNF protein levels in the prefrontal cortex in stressed rats." | 5.38 | Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. ( Abelaira, HM; Fries, GR; Kapczinski, F; Quevedo, J; Réus, GZ; Stringari, RB, 2012) |
| "Catatonia is a syndrome with protean manifestations and multiple aetiologies." | 5.37 | Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery. ( Jean-Baptiste, M; Mukai, Y; Two, A, 2011) |
| "Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo." | 5.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "We conducted a randomized, double-blind, placebo-controlled, parallel-group study of both memantine and constraint-induced aphasia therapy (CIAT) on chronic poststroke aphasia followed by an open-label extension phase." | 5.14 | Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. ( Barbancho, MA; Berthier, ML; Dávila, G; Green, C; Higueras, C; Lara, JP; Pulvermüller, F, 2009) |
| "In the present study we investigated the effect of the N-methyl-D-aspartic acid (NMDA) receptor antagonist memantine (30 mg/d) on the intensity of chronic phantom limb pain (PLP) and cortical reorganization." | 5.11 | A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. ( Birbaumer, N; Braun, C; Flor, H; Kiefer, RT; Preissl, H; Töpfner, S; Unertl, K; Wiech, K, 2004) |
| "In a randomized, double-blinded and cross-over study, the analgesic effect of memantine (a drug which reduces the excitability of sensitized neurons in the dorsal horn) was examined in 19 patients with chronic pain after nerve injury." | 5.09 | Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. ( Gottrup, H; Jensen, TS; Kristensen, AG; Nikolajsen, L, 2000) |
| "With no electrical neuromodulation, memantine and L-NAPNA abolished the cystitis-induced bladder contractions for approximately 4 and approximately 37 min, respectively." | 3.73 | Interaction between neurotransmitter antagonists and effects of sacral neuromodulation in rats with chronically hyperactive bladder. ( Mense, S; Riazimand, SH, 2005) |
| "A series of mutual prodrugs derived from gabapentin, pregabalin, memantine, venlafaxine were synthesized and their pharmacological properties to treat neuropathic pain were investigated in a rat model of chronic sciatic nerve constriction injury (CCI)." | 3.72 | Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury. ( Bo-Hua, Z; He, L; Hong-Ju, Y; Jun-Wei, W; Nan, Z; Wei-Guo, S; Wei-Xiu, Y; Zhe-Hui, G; Zheng-Hua, G; Zhi-Pu, L; Zhong-Wei, J, 2004) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "Memantine was shown to reduce pain intensity in CTTH patients, albeit to a limited extent." | 2.74 | Memantine for prophylaxis of chronic tension-type headache--a double-blind, randomized, crossover clinical trial. ( Bendtsen, L; Lindelof, K, 2009) |
| " The administration of a higher dosage is probably not tolerable." | 2.71 | Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain--results of a randomized double-blinded, placebo-controlled trial. ( Dertwinkel, R; Hosbach, I; Maier, C; Mansourian, N; Schwenkreis, P; Senne, I; Skipka, G; Tegenthoff, M; Zenz, M, 2003) |
| "16 patients with Alzheimer's disease were treated with akatinol memantine." | 2.69 | [Akatinol memantin in Alzheimer's disease: clinico-immunological correlates]. ( Androsova, LV; Selezneva, ND, 2000) |
| "Memantine was well tolerated in all studies." | 2.53 | Memantine for the Treatment of Phantom Limb Pain: A Systematic Review. ( Britt, RB; Brown, JN; Loy, BM, 2016) |
| "Memantine treatment reversed anhedonia and the increase of adrenal gland weight, normalized corticosterone levels and increased BDNF protein levels in the prefrontal cortex in stressed rats." | 1.38 | Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. ( Abelaira, HM; Fries, GR; Kapczinski, F; Quevedo, J; Réus, GZ; Stringari, RB, 2012) |
| "Catatonia is a syndrome with protean manifestations and multiple aetiologies." | 1.37 | Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery. ( Jean-Baptiste, M; Mukai, Y; Two, A, 2011) |
| " Thus, studies on the prevention and management of chronic pain should focus on preemptive or long-term administration of NMDA receptor antagonists." | 1.32 | Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. ( Aliev, K; Belozertseva, IV; Bespalov, AY; Danysz, W; Malyshkin, AA; Medvedev, IO; Parsons, CG; Sevostianova, NY; Sukhotina, IA; Zvartau, EE, 2004) |
| "In the chronic ocular hypertension model there was 37% decrease in RGCs after 3 weeks of elevated intraocular pressure." | 1.31 | Neuroprotective effect of memantine in different retinal injury models in rats. ( Ruiz, G; Schwartz, M; Wheeler, LA; WoldeMussie, E; Yoles, E, 2002) |
| " The current study determined whether the chronic administration of either a non-competitive N-methyl-D-aspartate- (NMDA-) sensitive receptor antagonist, memantine, or a selective cyclooxygenase-2 (COX2)/lipoxygenase inhibitor, CI987, could provide significant neuroprotection from the cytotoxic effects of LPS-induced neuroinflammation." | 1.31 | The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. ( Danysz, W; Hauss-Wegrzyniak, B; Wenk, GL; Willard, LB, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 18 (72.00) | 29.6817 |
| 2010's | 4 (16.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schaefer, M | 1 |
| Sarkar, S | 1 |
| Theophil, I | 1 |
| Leopold, K | 1 |
| Heinz, A | 1 |
| Gallinat, J | 1 |
| Light, GA | 1 |
| Zhang, W | 1 |
| Joshi, YB | 1 |
| Bhakta, S | 1 |
| Talledo, JA | 1 |
| Swerdlow, NR | 1 |
| Loy, BM | 1 |
| Britt, RB | 1 |
| Brown, JN | 1 |
| Lindelof, K | 1 |
| Bendtsen, L | 1 |
| Recla, JM | 1 |
| Sarantopoulos, CD | 1 |
| Berthier, ML | 1 |
| Green, C | 1 |
| Lara, JP | 1 |
| Higueras, C | 1 |
| Barbancho, MA | 1 |
| Dávila, G | 1 |
| Pulvermüller, F | 1 |
| Rosi, S | 1 |
| Ramirez-Amaya, V | 1 |
| Vazdarjanova, A | 1 |
| Esparza, EE | 1 |
| Larkin, PB | 1 |
| Fike, JR | 1 |
| Wenk, GL | 2 |
| Barnes, CA | 1 |
| Henry, KA | 1 |
| Réus, GZ | 1 |
| Abelaira, HM | 1 |
| Stringari, RB | 1 |
| Fries, GR | 1 |
| Kapczinski, F | 1 |
| Quevedo, J | 1 |
| Mukai, Y | 1 |
| Two, A | 1 |
| Jean-Baptiste, M | 1 |
| WoldeMussie, E | 2 |
| Yoles, E | 1 |
| Schwartz, M | 1 |
| Ruiz, G | 2 |
| Wheeler, LA | 1 |
| Maier, C | 1 |
| Dertwinkel, R | 1 |
| Mansourian, N | 1 |
| Hosbach, I | 1 |
| Schwenkreis, P | 1 |
| Senne, I | 1 |
| Skipka, G | 1 |
| Zenz, M | 1 |
| Tegenthoff, M | 1 |
| Flor, H | 2 |
| Findlay, DJ | 1 |
| Connelly, PJ | 1 |
| Wiech, K | 1 |
| Kiefer, RT | 1 |
| Töpfner, S | 1 |
| Preissl, H | 1 |
| Braun, C | 1 |
| Unertl, K | 1 |
| Birbaumer, N | 1 |
| Hong-Ju, Y | 1 |
| He, L | 1 |
| Wei-Guo, S | 1 |
| Nan, Z | 1 |
| Wei-Xiu, Y | 1 |
| Zhong-Wei, J | 1 |
| Jun-Wei, W | 1 |
| Zheng-Hua, G | 1 |
| Bo-Hua, Z | 1 |
| Zhi-Pu, L | 1 |
| Zhe-Hui, G | 1 |
| Medvedev, IO | 1 |
| Malyshkin, AA | 1 |
| Belozertseva, IV | 1 |
| Sukhotina, IA | 1 |
| Sevostianova, NY | 1 |
| Aliev, K | 1 |
| Zvartau, EE | 1 |
| Parsons, CG | 1 |
| Danysz, W | 2 |
| Bespalov, AY | 1 |
| Hare, WA | 1 |
| Lai, RK | 1 |
| Ton, H | 1 |
| Chun, T | 1 |
| Wheeler, L | 1 |
| Riazimand, SH | 1 |
| Mense, S | 1 |
| Spengos, K | 1 |
| Theleritis, C | 1 |
| Paparrigopoulos, T | 1 |
| Ossowska, G | 1 |
| Klenk-Majewska, B | 1 |
| Szymczyk, G | 1 |
| Spanagel, R | 1 |
| Kornhuber, J | 1 |
| Nikolajsen, L | 1 |
| Gottrup, H | 1 |
| Kristensen, AG | 1 |
| Jensen, TS | 1 |
| Androsova, LV | 1 |
| Selezneva, ND | 1 |
| Willard, LB | 1 |
| Hauss-Wegrzyniak, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study[NCT00148590] | Phase 3 | 24 participants (Actual) | Interventional | 2005-11-30 | Terminated | ||
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study[NCT00148616] | Phase 3 | 13 participants (Actual) | Interventional | 2004-04-30 | Terminated | ||
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| Effects of Combining Donepezil, Intensive Language Rehabilitation and Transcranial Direct Current Stimulation on Language Recovery and Brain Reorganization in Chronic Post-stroke Aphasia[NCT04134416] | Phase 3 | 20 participants (Actual) | Interventional | 2019-01-08 | Completed | ||
| Randomized Controlled Trial of Exercise Therapy in Combination With Central Nervous System-targeted Treatment Compared With Exercise Therapy Alone for Treatment of People With Knee Osteoarthritis[NCT03681613] | 104 participants (Anticipated) | Interventional | 2019-01-07 | Recruiting | |||
| Double Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients Victims of Landmines With Phantom Limb Pain[NCT01872481] | Phase 3 | 54 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial[NCT01653457] | Phase 3 | 60 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for memantine and Chronic Disease
| Article | Year |
|---|---|
Memantine for the Treatment of Phantom Limb Pain: A Systematic Review.
Topics: Acute Disease; Chronic Disease; Excitatory Amino Acid Antagonists; Humans; Memantine; Phantom Limb | 2016 |
Cortical reorganisation and chronic pain: implications for rehabilitation.
Topics: Back Pain; Biofeedback, Psychology; Chronic Disease; Excitatory Amino Acid Antagonists; Humans; Mema | 2003 |
Memantine (Ebixa) in the later stages of dementia.
Topics: Antiparkinson Agents; Chronic Disease; Clinical Trials as Topic; Dementia; Dementia, Vascular; Human | 2003 |
9 trials available for memantine and Chronic Disease
| Article | Year |
|---|---|
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
Topics: Adult; Antipsychotic Agents; Auditory Perception; Chronic Disease; Cortical Synchronization; Cross-O | 2017 |
Memantine for prophylaxis of chronic tension-type headache--a double-blind, randomized, crossover clinical trial.
Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; | 2009 |
Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia.
Topics: Adult; Aged; Analysis of Variance; Aphasia; Chronic Disease; Double-Blind Method; Drug Administratio | 2009 |
Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia.
Topics: Adult; Aged; Analysis of Variance; Aphasia; Chronic Disease; Double-Blind Method; Drug Administratio | 2009 |
Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia.
Topics: Adult; Aged; Analysis of Variance; Aphasia; Chronic Disease; Double-Blind Method; Drug Administratio | 2009 |
Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia.
Topics: Adult; Aged; Analysis of Variance; Aphasia; Chronic Disease; Double-Blind Method; Drug Administratio | 2009 |
Memantine for the prophylaxis of chronic tension-type headache.
Topics: Area Under Curve; Chronic Disease; Dopamine Agents; Double-Blind Method; Female; Humans; Memantine; | 2009 |
Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain--results of a randomized double-blinded, placebo-controlled trial.
Topics: Adult; Aged; Chronic Disease; Demography; Double-Blind Method; Excitatory Amino Acid Antagonists; Fe | 2003 |
A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain.
Topics: Adult; Amputation, Surgical; Chronic Disease; Cross-Over Studies; Double-Blind Method; Excitatory Am | 2004 |
Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study.
Topics: Adult; Aged; Amputation, Surgical; Amputation, Traumatic; Analgesics; Chronic Disease; Cross-Over St | 2000 |
[Akatinol memantin in Alzheimer's disease: clinico-immunological correlates].
Topics: Aged; Alzheimer Disease; Chronic Disease; Excitatory Amino Acid Antagonists; Female; Humans; Interle | 2000 |
13 other studies available for memantine and Chronic Disease
| Article | Year |
|---|---|
Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy?
Topics: Analgesics; Chronic Disease; Drug Therapy, Combination; Fibromyalgia; gamma-Aminobutyric Acid; Human | 2009 |
Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine.
Topics: Animals; Brain Mapping; Cells, Cultured; Chronic Disease; Cytoskeletal Proteins; Disease Models, Ani | 2009 |
Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats.
Topics: Adrenal Glands; Anhedonia; Animals; Brain Chemistry; Brain-Derived Neurotrophic Factor; Chronic Dise | 2012 |
Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; Combined Modality Therapy; Do | 2011 |
Neuroprotective effect of memantine in different retinal injury models in rats.
Topics: Action Potentials; Animals; Cell Count; Cell Survival; Chronic Disease; Electrophysiology; Excitator | 2002 |
Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.
Topics: Amines; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal | 2004 |
Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain.
Topics: Animals; Chronic Disease; Dizocilpine Maleate; Electrophysiology; Excitatory Amino Acid Antagonists; | 2004 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.
Topics: Administration, Oral; Animals; Cell Count; Chronic Disease; Disease Models, Animal; Electroretinogra | 2004 |
Interaction between neurotransmitter antagonists and effects of sacral neuromodulation in rats with chronically hyperactive bladder.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Anilides; Animals; Arginine; Chronic Disease; Cystitis; Electr | 2005 |
Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach?
Topics: Aged; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Excitatory Amino Acid | 2008 |
The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats.
Topics: Aggression; Animals; Chronic Disease; Dizocilpine Maleate; Electroshock; Excitatory Amino Acid Antag | 1997 |
[Glutamate receptor agonists and alcohol dependence. Preclinical findings].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Chronic Disease; Disease Models, Animal; Human | 1999 |
The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition.
Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cholinergic Fibers; Chronic Disease | 2000 |